<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-158284</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Kidney disease and psoriasis. A new comorbidity?</dc:title>
<dc:description xml:lang="en">Psoriasis is a chronic inflammatory disease that has been associated with cardiovascular and metabolic comorbidities, particularly in young patients and patients with more severe forms of the disease. Recent studies have also linked psoriasis to kidney disease, and this would seem only logical, as the kidney is both a target of classic cardiovascular risk factors and susceptible to the toxic effects of some of the traditional drugs used to control psoriasis. In this article, we would like to draw readers&#146; attention to this recently described comorbidity and stress the importance of early detection, as once chronic kidney disease develops, it cannot be reversed. When evaluating patients with psoriasis, particularly when they are candidates for systemic therapy, we believe it is important to order laboratory tests including glomerular filtration rate and a simple urine test to screen for albuminuria (albumin/creatinine ratio) (AU)</dc:description>
<dc:creator>González-Parra, E</dc:creator>
<dc:creator>Daudén, E</dc:creator>
<dc:creator>Carrascosa, JM</dc:creator>
<dc:creator>Botella, R</dc:creator>
<dc:creator>Olveira, A</dc:creator>
<dc:creator>Rivera, R</dc:creator>
<dc:creator>Bonanad, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La psoriasis es un proceso inflamatorio crónico que se ha asociado con comorbilidades cardiovasculares y metabólicas, especialmente las formas más graves y en pacientes jóvenes. Estudios recientes relacionan también la psoriasis con enfermedad renal, y parece lógico que sea así porque, por un lado, el riñón es un órgano diana de los factores de riesgo cardiovascular clásicos, y además, algunos de los tratamientos clásicos empleados para controlar la psoriasis tienen toxicidad renal. Con este artículo queremos hacer una llamada de atención sobre esta comorbilidad recientemente descrita; es fundamental su detección precoz porque una vez instaurada, la enfermedad renal crónica es irreversible. Consideramos importante que en el estudio basal de todo paciente con psoriasis, especialmente aquellos que van a recibir terapia sistémica, se analice la función renal con una analítica de sangre con filtrado glomerular y un análisis sencillo de orina para estudiar la albuminuria (relación albúmina/creatinina) (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;107(10): 823-829, dic. 2016. tab</dc:source>
<dc:identifier>ibc-158284</dc:identifier>
<dc:title xml:lang="es">Enfermedad renal y psoriasis. ¿Una nueva comorbilidad?</dc:title>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d422^s22016</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d7849^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12002^s22016</dc:subject>
<dc:subject>^d2359^s22012</dc:subject>
<dc:subject>^d7849^s22012</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d12002^s22032</dc:subject>
<dc:subject>^d6063^s22031</dc:subject>
<dc:subject>^d38340</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d422^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>201612</dc:date>
</metadata>
</record>
</ibecs-document>
